BERKELEY, Calif., Oct. 1, 2019,/PRNewswire/ — Today, the U.S. Patent and Trademark Office (USPTO) granted a brand new CRISPR-Cas9 patent to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier masking new methods of the gene-editing era in prokaryotic cells. The new patent (U.S. Patent No. 10,428,352) concentrates on binding modes of cleaving a goal DNA in a prokaryotic cellular using Cas9 protein and unmarried molecule DNA targeting RNAs. This patent also especially covers those techniques in bacterial cells.
This is the 5th consecutive week that the USPTO has awarded a CRISPR-Cas9 patent to UC, which has immensely accelerated the compositions and strategies protected in the portfolio. The university’s overall portfolio includes 16 patents, marking the largest CRISPR-Cas9 patent portfolio inside you. S ., and will upward thrust to 18 in the coming weeks once different applications that the USPTO has allowed are issued as patents. The substantial portfolio covers compositions and methods for the CRISPR-Cas9 gene-modifying generation, which includes concentrating on and editing genes and modulating transcription in any setting, including within plant, animal, and human cells.
“The non-stop issuance of CRISPR-Cas9 patents to UC provides enormous new compositions and techniques to our burgeoning portfolio that has quickly become the widest-ranging for the era,” stated Eldora L. Ellison, Ph.D., lead patent strategist on CRISPR-Cas9 subjects for UC and a Director at Sterne, Kessler, Goldstein & Fox. “We are thrilled via the USPTO’s ongoing popularity of the Doudna-Charpentier team’s management associated with CRISPR-Cas9.”
The Doudna-Charpentier group that invented the CRISPR-Cas9 DNA focused on generation blanketed Jennifer Doudna and Martin Jinek at the University of California, Berkeley; Emmanuelle Charpentier (then of Umea University); and Krzysztof Chylinski at the University of Vienna. The techniques covered with the aid of the latest patent, as well as the alternative compositions and methods claimed in UC’s previously issued patents and people set to the problem, were blanketed some of the CRISPR-Cas9 gene enhancing generation work disclosed first by way of the Doudna-Charpentier crew in its May 25, 2012 priority patent utility.
Additional CRISPR-Cas9 patents in this team’s portfolio consist of 10,000,772; 10,113,167; 10,227,611; 10,266,850; 10,301,651; 10,308,961; 10,337,029; 10,351,878; 10,358,658; 10,358,659; 10,385,360; 10,400,253; 10,407,697; 10,415,061; and 10,421,980. These patents aren’t a part of the PTAB’s recently declared interference among 14 UC patent programs, a couple of formerly issued Broad Institute patents, and one software, which jeopardizes all of Broad’s CRISPR patents concerning eukaryotic cells.
International patent places of work have also diagnosed the Doudna-Charpentier crew’s pioneering innovations, similar to the 16 patents granted in the U.S. To date. The European Patent Office (representing more than 30 countries), in addition to patent places of work inside the United Kingdom, China, Japan, Australia, New Zealand, Mexico, and different international locations, has issued patents for the use of CRISPR-Cas9 gene editing in all forms of cells.
The University of California has an extended-status dedication to developing and observing its patented technologies, such as CRISPR-Cas9, to better humankind. With its open-licensing policies, UC allows nonprofit and instructional institutions to apply the era for non-industrial academic and studies functions.
In the case of CRISPR-Cas9, UC has also advocated the enormous commercialization of the technology through its specific license with Caribou Biosciences, Inc. Of Berkeley, California. Caribou has sublicensed this patent family to numerous international agencies and Intellia Therapeutics, Inc for human healing programs. Additionally, Dr. Charpentier has licensed the generation to CRISPR Therapeutics AG and ERS Genomics Limited.